Well that seems unreasonable? Double-blind just gives better comparability of results with lower N. Statistics wouldn't object to, say, giving all Italian patients the treatment and most Chinese patients not. You'd just end up with a more complex model and wider uncertainty, but if the medicine worked on a noticeable scale, you'd pick it up eventually.
